Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olopatadine + ketorolac
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
A fixed-dose combination of **olopatadine** (an antihistamine and mast cell stabilizer) and **ketorolac** (a non-steroidal anti-inflammatory drug) in ophthalmic solution, formulated for topical administration to the eye. Olopatadine inhibits histamine release and stabilizes mast cells, reducing allergic inflammatory reactions; ketorolac inhibits cyclooxygenase (COX), blocking prostaglandin synthesis that drives ocular inflammation, hyperemia, and pain. This combination is designed to provide both rapid allergy symptom relief and reduction of inflammation for the treatment of **allergic conjunctivitis** and other ocular surface allergic disorders[1][2][4].
- Brand names
- Sclepat-KT
- Other names
- olopatadine hydrochloride + ketorolac tromethamineketorolac + olopatadine
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on olopatadine + ketorolac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olopatadine + ketorolac.